The Brussels Pharmaceuticals Conference 2010

5 May 2010, Brussels, Belgium.
The Brussels Pharmaceuticals Conference will be held on the 5th May 2010. This high-level event will provide a unique opportunity for key stakeholders to discuss the current developments in European pharmaceutical policy. This one-day conference aims to reflect on the progress being made in meeting the objective of the European Commission's Pharmaceutical Package to provide safe, innovative and accessible medicines to European citizens. By bringing together high-level speakers from both the research based and generic pharma Industry, NGO's and EU Institutions, this Forum Europe conference will assess the relative merits and weaknesses of the regulatory measures proposed and seek to find consensus and agreement on how to move forward.

Topics to be discussed include:

  • The proposed strengthening of the EU pharmacovigilance system
    The proposal concerning Pharmacovigilance sets out the need to strengthen existing legislation on the monitoring of post market drug safety in order to ensure that adverse drug reactions are correctly reported and monitored. This session will address a number of questions including: What measures can be taken to ensure that these recommendations are applied uniformly across member states? What will be the role of the European Medicine Agencies Eudravigilance database? Can lessons be learnt from the United States’ Pharmacovigilance system?
  • Counterfeit medicines and the European supply chain
    As the prevalence of access to counterfeit drugs increases both online and in member states’ legal supply chains, what regulatory measures can be taken to protect European Citizens? What are the roles and responsibilities of the pharmaceutical industry itself in ensuring the traceability of its medicines from production line to patient via wholesaler and pharmacist? Should the rules on Parallel Pharmaceutical Trade be tightened? How can the sale of counterfeit drugs on the internet be curbed?
  • Information to Patients: ensuring the right balance
    One of the most controversial aspects of the Pharmaceutical Package: the proposal concerning information to patients recommends a change in legislation that would allow pharmaceutical companies to provide information directly to the patient for the first time. With the debate currently stalled in parliament, where does the balance lie in terms of improvements in the internal market and consumer privacy and protection?

For further information and registration, please visit:
http://www.pharma-policy.eu

About Forum Europe
Based in Cardiff and with offices in Brussels at the heart of the European Union, Forum Europe specialises in EU focussed political and economic conferences and events. These events are organised with clients and partners and aim to progress ideas and actions on important issues, all within a balanced and neutral setting.

Founded by Giles Merritt, columnist for the International Herald Tribune and former Brussels correspondent at the Financial Times and headed by a team of EU events specialists with over 19 years of experience, Forum Europe’s strategic services can maintain and develop your networks at EU level, and also deliver forums where key issues can be aired and debated.

Forum Europe works successfully with businesses, institutions and governments alike and its expertise, through the medium of events, lies in understanding and interpreting the processes and political issues within the EU.

For more information, visit http://www.forum-europe.com

Most Popular Now

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...